Nanologica, a life sciences company that makes silica-based peptides for the pharmaceutical industry, acquired CDMO Ardena’s Syntagon manufacturing facility in a stock deal valued at 8.6 million Swedish kroner ($961,000).
Under terms of the deal, the Syntagon facility located in Södertälje, Sweden, and its 45 employees will operate as a subsidiary of Nanologica under the Syntagon name.
Annette Roos, chief executive of the Ardena division, will stay on in her current position, Nanologica said in a Jan. 29 press release. Jeremie Trochu, Ardena’s chief executive, is expected to be elected as a new member of the Nanologica board when the company holds a special shareholder meeting in early March.
The Södertälje facility specializes in the production of active pharmaceutical ingredients and can work on projects ranging from early lead molecules to larger-scale production, according to the release. Nanologica has prior experience with the site as a client.
“The acquisition of Syntagon takes Nanologica to a whole new level and gives us the opportunity to accelerate the group’s developmental,” Andreas Bhagwani, Nanologica’s CEO, said in a statement. “The acquisition also gives us access to premises that are better suited to our current business and that provide us with an infrastructure to develop new products and a complement to our current contract producer of silica.”
Nanologica expects the facility to make a material contribution to its earnings this year. The site had sales of 80 million Swedish kroner ($8.9 million) in 2025, the company said. Syntagon was founded in 1999 and was acquired by Ardena in 2018.
Ardena, based in Belgium, garnered industry attention in October 2024 when it snapped up Catalent’s oral solids development and small-scale manufacturing facility in Somerset, New Jersey, for an undisclosed price. That facility had served as Catalent’s corporate headquarters before it moved to Florida.
By December of that year, Catalent’s $16.5 billion sale to Novo Holdings was completed.